Press release
Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Innovation - DelveInsight | NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen
Natural Killer NK Cell Lymphoma Pipeline
DelveInsight's "Natural Killer NK Cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Natural Killer NK Cell Lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Natural Killer NK Cell Lymphoma drugs, the Natural Killer NK Cell Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Natural Killer NK Cell Lymphoma Pipeline Report
• DelveInsight's Natural Killer NK Cell Lymphoma Pipeline analysis depicts a robust space with 100+ active players working to develop 140+ pipeline drugs for Natural Killer NK Cell Lymphoma treatment.
• The leading Natural Killer NK Cell Lymphoma companies include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others are evaluating their lead assets to improve the Natural Killer NK Cell Lymphoma treatment landscape.
• Key Natural Killer NK Cell Lymphoma pipeline therapies in various stages of development include ALT 803, Bemarituzumab, Monalizumab, NKTR-214 (Bempegaldesleukin), Nidanilimab, Pidilizumab, SD-101, BVAC-C, PD-L1.t-haNK, K-NK002, Enkastim, ALECSAT, CellProtect, Nk-92, haNk, MG4101, Imprime PGG, Lirilumab, IPH4102, AFM-13, WU-NK-101, ABX196, AFM24, PNK-007, Allogeneic Natural Killer Cell Therapy (oNKord), FLYSYN, KNK-ID-101, GTB-3550, CAR-NK cells, DF1001, DF-6002, NKG2D-ACE2 CAR-NK Cells, AB-101, SNK01, NKTR-225, and others.
• In August 2024, Indapta Therapeutics received FDA IND clearance for its Phase 1 trial of IDP-023, a g-NK cell therapy for progressive multiple sclerosis.
• In June 2024, GT Biopharma secured FDA IND clearance to initiate a Phase 1 trial of GTB-3650 for CD33+ leukemia.
• In May 2024, the FDA granted orphan drug designation to IGNK001 (Gengleucel) for the treatment of acute myeloid leukemia (AML).
• In April 2024, the FDA also granted orphan drug designation to IGNK001 (Gengleucel) for AML.
Request a sample and discover the recent breakthroughs happening in the Natural Killer NK Cell Lymphoma pipeline landscape @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Natural Killer NK Cell Lymphoma Overview
Natural killer cells, also known as NK cells, are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and virus-infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production.
NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways.
Find out more about Natural Killer NK Cell Lymphoma medication @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Natural Killer NK Cell Lymphoma Treatment Analysis: Drug Profile
Monalizumab: Innate Pharma
Monalizumab (IPH2201) is a first-in-class humanized IgG4 antibody that targets NKG2A receptors on tumor-infiltrating cytotoxic NK and CD8 T cells. Developed by Innate Pharma, it is currently in Phase III trials for Squamous Cell Carcinoma of the Head and Neck and Phase II for gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. Additionally, it is in Phase I trials for advanced solid tumors and hematologic malignancies.
NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
NKTR-214 is designed to enhance the body's cancer-fighting immune response by expanding tumor-infiltrating lymphocytes (TILs), including cancer-killing T cells and NK cells. It works by targeting CD122-specific receptors on CD8+ effector T cells and NK cells, which are crucial for immune cell proliferation. CD122, also known as the Interleukin-2 receptor beta subunit, plays a key role in boosting these immune responses.
Key Natural Killer NK Cell Lymphoma Therapies and Companies
• Monalizumab: Innate Pharma
• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics
• ALT 803: ImmunityBio
• ALECSAT: CytoVac
• PNK-007: Celularity
Learn more about the novel and emerging Natural Killer NK Cell Lymphoma pipeline therapies @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Natural Killer NK Cell Lymphoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intracranial
• Intramuscular
• Intratumoral
• Intravenous
• Intravenous
• Parenteral
• Subcutaneous
By Molecule Type
• Small molecule
• Antibodies
• Beta Glucans
• CAR-NK cell therapy
• Cell Therapy
• Gene therapies
• Glycolipid
• NK Cell therapy
• NK T-Cell therapy
• Oligodeoxyribonucleotides
• Proteins
• RNA
• Stem cell therapies
• Vaccines
Scope of the Natural Killer NK Cell Lymphoma Pipeline Report
• Coverage: Global
• Key Natural Killer NK Cell Lymphoma Companies:ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others.
• Key Natural Killer NK Cell Lymphoma Pipeline Therapies: ALT 803, Bemarituzumab, Monalizumab, NKTR-214 (Bempegaldesleukin), Nidanilimab, Pidilizumab, SD-101, BVAC-C, PD-L1.t-haNK, K-NK002, Enkastim, ALECSAT, CellProtect, Nk-92, haNk, MG4101, Imprime PGG, Lirilumab, IPH4102, AFM-13, WU-NK-101, ABX196, AFM24, PNK-007, Allogeneic Natural Killer Cell Therapy (oNKord), FLYSYN, KNK-ID-101, GTB-3550, CAR-NK cells, DF1001, DF-6002, NKG2D-ACE2 CAR-NK Cells, AB-101, SNK01, NKTR-225, and others.
Dive deep into rich insights for drugs used for Natural Killer NK Cell Lymphoma treatment; visit @ https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Natural Killer NK Cell Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Natural Killer NK Cell Lymphoma Pipeline Therapeutics
6. Natural Killer NK Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Natural Killer NK Cell Lymphoma Pipeline: Late-Stage Products (Phase III)
8. Natural Killer NK Cell Lymphoma Pipeline: Mid-Stage Products (Phase II)
9. Natural Killer NK Cell Lymphoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Innovation - DelveInsight | NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen here
News-ID: 3942900 • Views: …
More Releases from DelveInsight
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market Drivers, barriers, trends, and key market Genome Editing companies in the market.
To read more about the latest highlights related to the Genome Editing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/genome-editing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Genome Editing Market…
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness about Retinopathy of Prematurity management, improvements in neonatal care units, and increasing focus on preventive…
Chronic Kidney Disease Market Evolution: Novel Drugs, AI Integration, and Combin …
The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others, who are actively advancing the CKD…
More Releases for Cell
Cell Sorting Market Accelerates as Cell Therapy, Immuno-Oncology & Single-Cell R …
The rising focus on precision medicine, immunotherapy, and advanced cell-based research is driving the global cell sorting market into a high-growth phase. With expanding applications in stem cell therapy, CAR-T manufacturing, cancer immunology, and single-cell genomics, demand for accurate, high-purity cell isolation systems is stronger than ever. This release highlights key market trends, segmentation insights, technological innovations, and the factors shaping the future of cell sorting.
Download Full PDF Sample Copy…
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
